Abstract
Objective. To analyze the expression and clinical significance of miR-204 in the serum of patients with severe pneumonia (SP) and primary bronchial lung cancer (LC). Methods. 65 SP patients and 43 primary bronchial LC patients who were treated in the hospital from January 2017 to December 2018 were randomly selected as the SP group and LC group. At the same time, healthy patients from the physical examination department of the hospital were selected. 65 cases were the control group. QRT-PCR detected serum miR-204 expression and compared the differences between groups. The pathological data of patients were collected, and the relationship between serum miR-204 and the patient’s pathological data was compared; the area under the ROC curve and Kaplan–Meier curve were used to evaluate the diagnostic value of serum miR-204 for the two conditions and to explore the relationship between serum miR-204 and prognosis. Results. The serum miR-204 of the SP group was (0.43 ± 0.09), the serum miR-204 of the LC group was (0.40 ± 0.10), the serum miR-204 of the control group was (1.00 ± 0.09), and the miR-204 level of was significantly higher than that of the control group, and the difference between the groups was statistically significant ( P < 0.05). There was no significant difference in serum miR-204 levels between the SP group and the LC group ( P > 0.05). Serum miR-204 levels in SP patients with cumulative organs ≥3 were higher than those with cumulative organs <3, and the difference was statistically significant ( P < 0.001). In the LC group, in patients with stage III to IV and low and undifferentiated patients, the level of miR-204 was higher than that of stage I∼II and high and moderately differentiated patients, and the difference was statistically significant ( P < 0.001). The level of miR-204 in the two groups of patients (0.89 ± 0.10, 0.83 ± 0.13) who died of illness was significantly higher than that of the surviving patients (1.00 ± 0.11, 1.00 ± 0.10), and the difference was statistically significant ( P < 0.05); the survival rate of patients with high expression of miR-204 was higher than that of patients with low expression. The AUC of serum miR-204 level to SP and LC was 0.766 and 0.818, respectively. Conclusion. The level of miR-204 in the serum of SP patients and patients with primary bronchial LC was significantly lower than that of healthy people, and patients who died were lower than those who survived; the miR-204 in serum has a good diagnostic value for SP and LC and is related to the survival and prognosis of patients.
Highlights
Ere was no significant difference in serum miR-204 levels between the severe pneumonia (SP) group and the lung cancer (LC) group (P > 0.05)
According to the place where it is acquired, it can be divided into community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP); about 50,000 people die from pneumonia every year. 20%–60% of severe pneumonia (SP) patients require hospitalization due to the severity of the disease and the underlying disease or social factors [1, 2]. 10%–22% of inpatients who reach the diagnosis of SP need to be admitted to the intensive care unit (ICU) for treatment
According to whether patients in all groups died during the follow-up period, patients with SP and primary bronchial LC were divided into a death group and survival group. e serum miR-204 levels of all patients were divided into a high-expression group and low-expression group according to their medians, and the relationship between serum miR-204 and the prognosis of the two conditions was explored
Summary
Despite the use Evidence-Based Complementary and Alternative Medicine of antibiotics and emergency treatment measures, 44%–83% of patients still require mechanical ventilation when they are admitted to the ICU, and more than 50% of patients are complicated by septic shock, and the mortality rate is high [3]. SP is a type of pneumonia with severe disease, rapid progress, and poor prognosis. There are various treatment measures such as powerful anti-infective treatment and ventilator-assisted ventilation, SP has rapid changes in disease condition, complex inflammatory response, and multiple organ dysfunction syndrome (MODS), which is difficult to treat and expensive, and the prognosis is poor and the mortality rate is high [4, 5]. Treatments for NSCLC include chemotherapy, radiotherapy, and traditional Chinese medicine, but the prognosis is not ideal [10]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
